Analysis Group Researchers to Present at ISPE 2024
Event: 40th International Society for Pharmacoepidemiology (ISPE) Annual Meeting
Dates:
25–29 August 2024
Host:
International Society for Pharmacoepidemiology (ISPE)
Location:
Berlin, Germany
Analysis Group, a global leader in drug safety epidemiology and regulatory real-world evidence (RWE), will present two podium presentations and five research posters at the 40th annual meeting of the International Society for Pharmacoepidemiology (ISPE).
Vice President Marianne Cunnington is a coauthor of two podium presentations at the meeting:
Monday, August 26, 1:30 p.m. CEST, Convention Hall I D
- Applying the self-controlled case series to analyze safety endpoints in single-arm, open label extension studies: A case study of Belimumab for the treatment of systemic lupus erythematosus and risk of infection
Wednesday, August 28, 8:45 a.m. CEST, Room XV
- Impact of data source diversity on the distribution of key variables in pregnancy cohorts based on the ConcePTION pregnancy algorithm leveraging a random forest imputation model
Additionally, researchers from Analysis Group – including Managing Principals Mei Sheng Duh and Maral DerSarkissian; Vice Presidents Rose Chang, Marianne Cunnington, and Fan Mu; and Managers Catherine Nguyen and Erin Cook – will present five posters at the meeting on the following topics:
Poster Session A: Monday, August 26, 8:00 a.m.–6:00 p.m. CEST
- Poster No. 158: Comparative Effectiveness of ARB and ACEi for Cardiovascular Outcomes and Risk of Angioedema by Ethnicity: an Analysis in the UK Clinical Practice Research Datalink with Emulation of a Reference Trial (ONTARGET)
- Poster No. 108: Impact of Treatment of COVID-19 with Sotrovimab on Post-Acute COVID-19 Syndrome: An Analysis of National COVID Cohort Collaborative (N3C) Data
- Poster No. 070: NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
Poster Session B: Tuesday, August 27, 8:00 a.m.–6:00 p.m. CEST
- Poster No. 342: Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Poster Session C: Wednesday, August 28, 8:00 a.m.–1:30 p.m. CEST
- Poster No. 305: High Misclassification of Glycogen Storage Disease Type 1a in a US Electronic Medical Records Database – Insights from a Physician Note Review
Further details on the podium presentations and posters are available in our 2024 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.
Meet Our People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and life cycle management of pharmaceutical and vaccine products, with a particular focus on regulatory risk management strategies and product benefit-risk assessments. Dr. Cunnington’s research expertise includes the design, negotiation, and execution of real-world components of risk management plans for new product submission to regulators in the US, UK, EU, Japan, and South Korea, including studies of post-approval safety in the EU; post-marketing requirements and commitments in the US; and pregnancy registries. Prior to joining Analysis Group, she served in several senior epidemiology positions at pharmaceutical companies, including as the chair of GSK’s peer review forum for all pharmaceutical RWE projects; as a member of GSK’s Global Safety Board; as head of epidemiology at Novartis Vaccines; and as a managing board member of Innovative Medicines’ public-private partnership initiative to build an integrated European real-world data (RWD) network to monitor medication safety in pregnancy.